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Pre-existing renal disease promotes sepsis-induced
acute kidney injury and worsens outcome
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While it is known that risk of death from sepsis is higher
in patients with pre-existing chronic kidney disease its
mechanism is unknown. To study this we established a
two-stage mouse model where renal disease was first
induced by folic acid injection followed by sub-lethal cecal
ligation and puncture to induce sepsis. Septic mice with
pre-existing renal disease had significantly higher mortality,
serum creatinine, vascular permeability, plasma vascular
endothelial growth factor (VEGF) levels, bacteremia, serum
IL-10, splenocyte apoptosis and more severe septic shock
when compared to septic mice without pre-existing disease.
To evaluate the contribution of vascular and immunological
dysfunction, we treated the folate-septic mice with soluble
Flt-1 to bind VEGF and chloroquine to reduce splenocyte
apoptosis. These treatments together resulted in a significant
improvement in kidney injury, hemodynamics and survival.
Our study shows that the sequential mouse model mimics
human sepsis frequently complicated by pre-existing renal
disease and might be useful in evaluating preventive and
therapeutic strategies.
Kidney International (2008) 74, 1017–1025; doi:10.1038/ki.2008.346;
published online 16 July 2008
KEYWORDS: acute-on-chronic; cecal ligation puncture; VEBGF; SFlt-1;
chloroquine
Sepsis is the leading cause of death in critically ill patients and
the incidence of sepsis is increasing.1,2 Sepsis causes acute
kidney injury (AKI) and patients with both sepsis and AKI
show an especially high mortality rate.3 Chronic kidney
disease (CKD) is found in approximately 30% of AKI
patients in ICU4 and severe sepsis occurring in patients with
underlying chronic diseases (comorbidities) including CKD,
liver disease, and diabetes has an extremely high mortality
rate.1,5 These findings suggest that clinical sepsis and sepsis-
induced AKI are dramatically influenced by underlying
diseases, which may explain why simple animal models
of sepsis do not mimic human sepsis, and do not predict
human response to therapeutics.6 Developing a new animal
model that allow us to investigate the mechanism by which
preexisting CKD increases the mortality of sepsis might help
discovery efforts to improve the mortality of sepsis, because
the prevalence of CKD is increasing worldwide.
In the present study, we developed a new two-stage mouse
model that mimics sepsis in patients with preexisting renal
dysfunction. This ‘two-stage’ animal model consists of folic acid
(FA)-induced renal injury followed by a sublethal cecal ligation
and puncture (CLP) model of sepsis. FA injection induces renal
injury, as documented by an increase of serum creatinine (Cr),
about 60% decrease in glomerular filtration rate (GFR), and a
remarkable interstitial fibrosis within 2 weeks.7 Two weeks after
FA injection, we induced sepsis by using a clinically relevant
CLP sepsis model which we have established;8 animals are
treated with fluid resuscitation and antibiotics similar to septic
patients in an ICU. We then used this new two-stage FA-CLP
sepsis model to investigate the pathophysiological mechanisms
through which CKD increases sepsis mortality. We used
two agents that are known to modulate vascular (sFlt-1) and
inflammatory (chloroquine; CQ) dysfunction in sepsis. As
the two-stage model is sufficiently complex and models the
propensity of preexisting disease to dramatically increase
the risk of sepsis, we evaluated the effect of combination
therapy in this model that better mimics human sepsis.
RESULTS
FA-CLP mice showed higher mortality after sepsis with
amplified acute kidney injury
The protocol of the two-stage FA-CLP model is shown in
Figure 1. Blood urea nitrogen (BUN) and serum Cr of FA
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group at 48 h after injection were substantially higher than
vehicle (Veh) group. Although BUN and serum Cr decreased
at 2 weeks after injection, there was a significant and
persistent elevation of both BUN and Cr in the FA group.
GFR at 2 weeks after injection was 62% lower in the FA group
than in the Veh group (Table 1).
Sepsis induced by sublethal CLP surgery showed a
significantly higher mortality in the FA-CLP group compared
with the Veh-CLP group (FA-CLP 93%, Veh-CLP 18% at
96 h; Po0.05; Figure 2a). In the Veh-CLP group, BUN but
not serum Cr showed a modest increase following sublethal
CLP surgery. In contrast, BUN and serum Cr in the FA-CLP
group were both increased significantly at 18 h after CLP
surgery compared to those at 0 h (Figure 2b and c). Renal
morphologic evaluation was performed at 0 and 18 h after
CLP surgery. In accordance with previous reports,7,9 FA
induced patchy interstitial fibrotic lesions 2 weeks after
injection, although the cortical tubules in nonfibrotic areas
were grossly normal (Figure 2d and e). We found no
histological evidence of damage to other organs (data not
shown). We have reported previously that sepsis induced by
CLP caused renal tubular damage mainly consisting of
tubular vacuolization.8,10,11 In the present study, tubular
vacuolization was found in the cortex of Veh-CLP group and
nonfibrotic cortical area of FA-CLP (Figure 2f and g). The
number of vacuolized tubules in these areas was higher in the
FA-CLP group than in the Veh-CLP group (Figure 2h).
Severe septic shock and hyperkalemia in FA-CLP mice
Blood pressure (BP) and heart rate (HR) were measured in
conscious animals by radiotelemetry. Presepsis BP was
slightly, but not significantly, higher in FA-injected mice
than vehicle-injected mice. Sepsis induced by sublethal CLP
surgery caused mild decreases of BP and HR in Veh-CLP
mice. On the other hand, severe hypotension and decreased
HR were found in FA-CLP mice (Figure 3a and b).
Serum potassium levels of FA-CLP mice at 0 h (that is,
before CLP) were similar to those of Veh-CLP mice. Sepsis
induced hyperkalemia along with AKI in FA-CLP mice.
Bilateral nephrectomy induced higher serum potassium levels
than FA-CLP mice 18 h after surgery (Figure S1). However,
bilateral nephrectomized mice started to die later than FA-
CLP mice (time to death: FA-CLP, 41.5±5.8 h (n¼ 10);
bilateral nephrectomy, 51.3±3.7 h (n¼ 11); Po0.05),
although total survival rate were not significantly different
between these two groups. This suggests that hyperkalemia is
unlikely to be the primary cause of death in FA-CLP mice.
FA-CLP mice showed higher vascular permeability, plasma
VEGF
Vascular permeability was examined with Evans blue dye,
which binds to circulating albumin. Renal vascular perme-
ability in FA-CLP mice at 0 h was increased compared with
Veh-CLP (Po0.05). There was no difference in peritoneum
or lung vascular permeability before CLP. FA-CLP mice
showed a significantly higher vascular permeability compared
with Veh-CLP mice in kidney (6 h), peritoneum (6, 18 h),
and lung (6 h; Figure 4a–c). The plasma level of vascular
endothelial growth factor (VEGF), a growth factor known to
enhance vascular permeability,12 in FA-CLP mice was higher
than that in Veh-CLP mice before CLP. Sepsis significantly
increased plasma VEGF in FA-CLP compared with Veh-CLP
mice (6, 18 h). Moreover, bilateral nephrectomy dramatically
increased plasma VEGF 18 h after nephrectomy (Figure 4d).
These results suggest that the kidney plays an important role
in handling circulating VEGF. Recombinant sFlt-1 peptide
can bind to circulating VEGF and has been reported to
improve the survival of mouse sepsis models including
CLP.13,14 We found that treatment with sFlt-1 peptide
significantly reduced peritoneal, kidney, and lung vascular
permeability in FA-CLP mice, best seen at 6 h after CLP
(Figure 4a–c).
Bacterial count, splenocyte apoptosis, and serum IL-10
increased in FA-CLP mice
Sepsis induces a state of altered host defenses, which was
assessed via measurement of bacterial counts from blood and
peritoneal cavity, splenocyte apoptosis, and serum inter-
leukin-10 (IL-10) levels. FA-CLP mice showed higher
bacterial counts both in blood and peritoneal cavity
compared with Veh-CLP (Figure 5a and b). Splenocyte
apoptosis evaluated by activated caspase-3 immunohisto-
FA 48 h 2 wk
CLP 6 h 18 h
Sampling
Figure 1 | Two-stage mouse model of FA-induced renal injury
and subsequent sepsis with CLP surgery. Schema of FA-CLP
animal model protocol is shown.
Table 1 | Renal function after folic acid injection
BUN Serum Cr BUN Serum Cr GFR
48 h (mg per 100 ml) 48 h (mg per 100 ml) 2 wk (mg per 100 ml) 2 wk (mg per 100 ml) 2 wk (ll/min)
FA 204.9±14.2* 1.32±0.14* 50.3±3.2* 0.28±0.03* 162.0±20.2*
Veh 18.5±1.3 0.10±0.01 24.5±2.0 0.11±0.01 425.5±14.9
BUN, blood urea nitrogen; Cr, creatinine; FA, folic acid; GFR, glomerular filtration rate; Veh, vehicle.
Data are mean±s.e.m.
n=14–17 in BUN and serum Cr; n=5 in GFR measurement.
*Po0.05 versus Veh group.
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chemisty was not increased by FA injection alone. After CLP
surgery, the number of activated caspase-3 cells was higher in
FA-CLP compared with Veh-CLP mice at 18 h after CLP
surgery (Figure 5c). Serum IL-10 levels were not different
between FA-CLP and Veh-CLP mice 2 weeks after FA
injection. After induction of sepsis, FA-CLP mice showed
significantly higher serum IL-10 levels compared with Veh-
CLP mice (Figure 5d). CQ is reported to improve mortality
of several CLP models via improving splenocyte function,15
splenocyte apoptosis, and serum IL-10.16 In the current FA-
CLP model, we found that CQ treatment also significantly
attenuated the bacterial count in blood, splenocyte apoptosis,
and serum IL-10 levels. In contrast, CQ did not significantly
decrease peritoneal fluid bacterial counts (Figure 5a–d).
Liver damage and lung pathological damage in FA-CLP mice
There was no statistically significant difference of aspartate
aminotransferase and alanine aminotransferase between
FA-CLP and Veh-CLP mice, although both groups showed
increases of liver enzymes after CLP surgery (Figure 6a
and b). FA injection did not cause any lung damage (data not
shown). Although lung vascular leakage in FA-CLP mice at
6 h was significantly increased, there was no detectable
histological change (that is, increase of interstitial cellularity
and/or extension of cellular infiltrates into the alveolar space)
in either FA-CLP or Veh-CLP at 6 and 18 h after CLP (Figure
6c and d).
Combination treatment with soluble Flt-1 and chloroquine
improved survival of FA-CLP mice
As sFlt-1 peptide and CQ appear to affect sepsis by different
mechanisms, we treated FA-CLP mice with sFlt-1 and CQ,
alone or in combination. Each treatment alone tended to
decrease BUN and serum Cr levels 18 h after CLP surgery, but
only the combination treatment showed a statistically
significant protective effect (Figure 7a and b). Hypotension
and bradycardia after sepsis induction were improved only in
sFlt-1 and combination treatment groups (Figure 7c and d),
whereas CQ partially improved BP without improving HR at
all. In the survival analysis, sFlt-1 and CQ treatment
decreased mortality compared with control group individu-
ally (sFlt-1 40%, CQ 29%, control 12% at 96 h), however
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Figure 2 | Survival and kidney injury of FA-CLP model. (a) Survival analysis of FA-CLP (n¼ 14) and Veh-CLP (n¼ 17). (b, c) Renal function
of Veh-CLP and FA-CLP mice. BUN and serum Cr were measured 0 and 18 h after CLP (n¼ 14 in FA-CLP, n¼ 17 in Veh-CLP).
(d–g) Representative renal histology of (d, f) Veh-CLP and (e, g) FA-CLP at 18 h are shown with Masson’s trichrome staining. Original
magnification:  20 in (d, e) and  400 in (f, g). (h) Percentage of vacuolized tubules (n¼ 3 at 0 hr, n¼ 5 at 18 h per group). #Po0.05 versus
Veh-CLP. *Po0.05 versus CLP 0 h.
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only the combination treatment group showed a statistically
significant improvement of survival compared with the
control group (survival rate: 60% at 96 h, Po0.05 versus
FA-CLP; Figure 7e).
DISCUSSION
We have developed a new two-stage mouse model of FA-
induced renal injury and subsequent sepsis with CLP surgery.
This model replicated the clinical finding that preexisting
CKD amplifies sepsis-induced AKI, induces severe septic
shock, and worsens outcome in sepsis.1,4 We demonstrated
the participation of several different pathophysiological
mechanisms (that is, increased capillary permeability,
decreased bacteria clearance, and splenocyte apoptosis), and
the benefit of combination treatment with soluble Flt-1 and
CQ, compared to treatment with the individual agents.
Animal studies typically examine sepsis and related organ
failure in otherwise healthy animals, despite the inability of
simple sepsis models to predict human drug response6 and
numerous epidemiological studies of human sepsis that show
the importance of preexisting comorbidity.1,5 Angus et al.1
reported that 55% of 200,000 patients with severe sepsis had
underlying comorbidity. As CKD patients have been recently
recognized as being at high risk for cardiovascular death and
mortality from all causes,17,18 patients with CKD also have an
increased risk of morbidity and mortality of sepsis.1,19–22 In
one large multicenter study involving 30,000 critically ill
patients, 50% of AKI was associated with septic shock and
30% of AKI had preexisting renal dysfunction.4 A new animal
model that mimics the complexity of human sepsis is
required. To simulate CKD, we employed a mouse FA
injection model. This model causes acute tubular damage
with increases of BUN and serum Cr peaking 2 days after
injection, and mild renal dysfunction with remarkable
interstitial fibrosis were subsequently found after 2 weeks.
FA injection did not cause other organ damage (that is, liver
and lung), possibly because the rodent folate receptors are
highly expressed in the kidney23 and/or the kidney damage is
induced by chemical precipitation of FA in the renal tubules.
Although the FA-induced renal injury model does not show
any glomerular lesions nor does it progress to end-stage renal
disease, it does transiently mimic human CKD in terms of
decreased GFR (Table 1) and histologic evidence of kidney
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Figure 4 | Vascular permeability and plasma VEGF levels.
Evans blue dye leakage in (a) peritoneum, (b) kidney, and (c) lung
was measured at 0, 6, and 18 h after CLP (n¼ 4–8 per group).
(d) Plasma VEGF levels were measured at 0, 6, and 18 h after CLP
by ELISA (n¼ 5–6 per group). #Po0.05 versus Veh-CLP. *Po0.05
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damage (Figure 2e and f) as defined in the K/DOQI
guideline.24
Our study is the first ‘two-stage’ sepsis animal model that
consists of prior kidney injury followed by subsequent sepsis.
Previous ‘two-hit’ animal models of sepsis generally include
two closely adjacent ‘hits’ that mimic prior surgical
procedures, acute hemorrhagic shock or burns followed in
rapid succession by sepsis induced by CLP, endotoxin, or
bacteria injections.25–27 These two-hit models generate
substantially more severe sepsis than induced by sepsis alone.
This heightened susceptibility was also found in our current
two-stage acute-on-chronic disease animal model that
showed a higher mortality in animals with reduced renal
function (FA-CLP) compared with normal renal function
(Veh-CLP). FA-CLP mice had substantially increased AKI
and severity of septic shock, but not liver enzyme elevations
or lung inflammatory changes compared to Veh-CLP mice. It
is well known that severe shock and sepsis-induced AKI are
the most important predicting factors for sepsis out-
comes.28,29 Our data indicate that preexisting renal dysfunc-
tion worsens sepsis by amplifying additional renal damage
and promoting septic shock.
To verify these findings, we set up a second CKD model in
CD-1 mice utilizing a modified 5/6 nephrectomy ‘remnant
kidney’ model. CKD was confirmed by robust proteinuria,
increases in serum Cr and BUN, and histological evidence of
chronic glomerular changes and interstitial fibrosis at 4
weeks. Subsequent sublethal CLP produced significant
increases in BUN, aspartate aminotransferase, alanine
aminotransferase at 18 h in the CKD animals compared to
non-CKD animals; Cr was increased but not significantly (as
in the FA/sublethal model). There was also a trend toward
higher mortality within 18 h (Leelahavanichkul et al., un-
published data). Therefore the worsening of sepsis by
preexisting kidney disease is not limited to the FA model.
VEGF plays a critical role in promoting endothelial
survival and maintaining the microvasculature.30 On the
other hand, high levels of VEGF can cause vascular leakage by
destruction of vascular barrier function12 and are associated
with heightened severity of human sepsis.31,32 Interestingly,
plasma VEGF levels were already increased in FA-CLP mice
just before CLP and bilateral nephrectomy caused a large
increase of plasma VEGF. Increased plasma VEGF levels have
been reported in predialysis or hemodialyzed patients and
subtotal nephrectomized rats.33–35 VEGF production in
fibrotic kidney in mouse FA-induced renal injury model
was decreased.9 These data suggest that the kidney plays an
important role in removing VEGF from the systemic
circulation. Other factors induced by renal dysfunction
might enhance systemic VEGF production and/or suppress
VEGF degradation. Impaired handling of VEGF in FA-CLP
mice and CKD patients could contribute to the high
mortality from sepsis. In the present study, we found a
protective effect of sFlt-1 in our FA-CLP model that was
associated with a decrease in vascular permeability and
prevention of severe hypotension. Recently, two different
groups reported that VEGF plays an important pathophy-
siologic role in sepsis. Injection of recombinant human VEGF
worsened the survival of lipopolysaccharide-injected mice.14
Soluble Flt-1 (VEGF receptor-1) peptide injection improved
the survival in a lipopolysaccharide injection model and a
simple CLP model.13 Soluble Flt-1 treatment had multiple
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effects including attenuation of increased vascular perme-
ability, depression of cardiac function,13 and enhanced
proinflammatory cytokine productions.14 Soluble Flt-1
modulates sepsis by several different mechanisms and further
investigations are required to clarify the precise mechanisms
of action of sFlt-1 in this FA-CLP model.
Infectious complications in CKD patients are important
causes of their morbidity and mortality. CKD patients are at
significant risk of hospitalization for sepsis.19,22 It is reported
that mortality associated with systemic bacteremia is
significantly higher in patients with preexisting CKD (serum
Cr above 3 mg per 100 ml).21 Uremia is associated with
alterations in host defense systems and increases the risk of
bacterial infections through a number of possible mechan-
isms such as impaired neutrophil activation and deficient cell
immunity.36,37 In the present study, bacterial counts in blood
and peritoneal fluid after CLP-induced sepsis were signi-
ficantly higher in FA-CLP mice than Veh-CLP mice. We also
found significantly higher levels of anti-inflammatory
cytokine IL-10 in FA-CLP mice. It is reported that IL-10 in
septic patient serum could deactivate human monocytes38
and impaired antigen presentation of human monocytes
induced by lipopolysaccharide is dependent on IL-10.39
In human sepsis, apoptosis was detected dominantly in
lymphocytes40 and several strategies to decrease immune cell
apoptosis has been reported to improve the survival from
sepsis by CLP.41–43 FA-CLP mice showed more splenocyte
apoptosis after sepsis compared with Veh-CLP mice. It is
reported that CQ improved survival of CLP-induced sepsis
following hemorrhagic shock while increasing splenocyte
proliferation and IL-2 production.15 We also found that CQ
improved sepsis via decreasing splenocyte apoptosis and
serum IL-10 levels.16 In the present study, CQ treatment
improved bacteremia, decreased IL-10 levels, and splenocyte
apoptosis in FA-CLP mice.
Numerous basic research studies have investigated the
multiple pathophysiological mechanisms of sepsis. However,
clinical trials targeting specific pathways have not been
successful, with the possible exception of activated protein C,
although this is controversial.44 There are several possible
reasons.6 First, some of these drug targets (for example,
tumor necrosis factor-a) were selected on the basis of results
from animal models that do not replicate human sepsis. We
established our CLP model to replicate human sepsis and
sepsis-induced AKI by administrating fluid and broad-
spectrum antibiotics.8 In addition, we introduced a preexist-
ing comorbidity to mimic the common observation that
human sepsis occurs more commonly in patients with
underlying chronic diseases.1 Second, several therapies were
extremely narrowly focused (for example, target a single
proinflammatory cytokine). As discussed above, our FA-CLP
model is sufficiently complex because it includes both
preexisting renal dysfunction and polymicrobial sepsis.
Therefore, we treated FA-CLP mice with a combination of
agents that act on apparently different pathways; soluble Flt-1
for vascular dysfunction and CQ for altered host defense. The
survival advantage from the combination treatment was
statistically significant, whereas the individual treatments
were not. The highest survival rate and improved systemic
hemodynamics as measured by BP and HR in the combination
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treatment group suggests that multiple therapeutic interven-
tions may be required for the treatment of sepsis complicated
with comorbidity. We did not measure the therapeutic
window for the combination therapy; this needs to be tested
to determine whether this strategy might be considered to
preempt or treat patients with established sepsis and/or
sepsis-AKI.
In conclusion, we developed a new clinically relevant
murine two-stage model of sepsis in the setting of preexisting
renal dysfunction. This model replicated the clinical findings
of higher mortality of sepsis in CKD patients. We also found
that combination therapy of soluble Flt-1 and CQ, which
block vascular and immunological dysfunction, respectably
showed the best survival rate. Our results strongly suggest
that combination of complementary therapeutic approaches
might be needed to treat human sepsis.
MATERIALS AND METHODS
Folic acid injection and subsequent cecal ligation and
puncture model
All animal experiments were conducted in accordance with an
animal study protocol approved by the NIDDK animal care and use
committee. Eight-week-old male CD-1 mice (Charles River
Laboratories, Wilmington, MA, USA) were used. Mice were
administered FA (Sigma-Aldrich, St. Louis, MO, USA) intraper-
itoneally at a dose of 250 mg/kg in vehicle (0.2 ml of 0.3 mM
NaHCO3) or given vehicle alone. Two days later, 60–70% of the mice
developed AKI (defined as BUN4100 mg per 100 ml) as previously
described.45,46 In all experiments, we used animals only with
sufficient acute renal damage (BUN4100 mg per 100 ml) at 48 h
after FA injection.
CLP surgery was performed on FA-treated (FA-CLP) and
vehicle-treated mice (Veh-CLP) at 2 weeks after injection. Under
isoflurane anesthesia, a 4-0 silk ligature was placed 8 mm from the
cecal tip. The length of 8 mm was shown to cause sublethal sepsis in
normal CD-1 mouse.47 The cecum was punctured twice with a 21-
gauge needle and gently squeezed to express a 1 mm column of fecal
material. Prewarmed normal saline (NS; 1 ml) was injected
intraperitoneally. Treatment with fluid and antibiotic was started
at 6 h after surgery with subcutaneous injection of imipenem/
cilastatin (14 mg/kg) in 1 ml of NS. Animals were killed 6 and 18 h
after surgery for collecting specimens. In the survival study,
treatment was continued every 12 h with imipenem/cilastatin
(7 mg/kg) in 1 ml of NS.
Bilateral nephrectomy
Under isoflurane anesthesia, the kidneys were exposed from flank,
dissected, and removed after the pedicles were ligated using 4-0 silk
sutures. The wounds were closed in two layers using 6-0 nylon
sutures and surgical staples. Prewarmed NS (1 ml) was injected
intraperitoneally. Animals received antibiotics and fluid treatment at
6 h as described above and were killed 18 h after surgery or observed
for survival analysis.
Measurement of GFR in conscious mice
GFR was measured by fluorescein isothiocyanate labeled inulin
clearance.48 Blood samples were collected from the tail vein at 3, 7,
10, 15, 35, 55, and 75 min after single fluorescein isothiocyanate
labeled inulin (3.7 ml/g body weight) injection. Fluorescence was
determined by a Nanodrop-ND-3300 fluorescence spectrometer
(Nanodrop Technologies, Wilmington, DE, USA). GFR was
calculated using a two-compartment model of two-phase exponen-
tial decay.
Treatment of soluble Flt-1 and chloroquine
Recombinant human soluble Flt-1 domain D1-3 (Cell Sciences,
Canton, MA, USA) at the dose of 1 mg per mouse or an equal
volume of NS was injected intravenously every 3 h (four doses),
beginning 1 h after CLP.13 CQ (Sigma-Aldrich) at the dose of 50 mg/
kg or an equal volume of saline was administered by oral gavage at
3 h before CLP surgery. When testing combination treatment, mice
were randomly assigned to the following groups: sFlt-1 and CQ,
sFlt-1 and vehicle (peritoneally), CQ and vehicle (intravenously), or
vehicle only (peritoneally and intravenously).
Measurement of blood pressure and heart rate
The mean BP and HR were measured by radiotelemetry.49 A
telemeter catheter was implanted in the left carotid artery and
advanced to the aortic arch. The attached telemetry transmitter
(model TA11PA-C10, Data Sciences International, St Paul, MN,
USA) was placed in a subcutaneous pocket on the left flank 3–5 days
before CLP surgery. BP and HR data were analyzed from 9 h before
CLP surgery for 27 h.
Measurement of blood chemistry, vascular endothelial
growth factor, and IL-10
BUN and serum Cr was measured by a modified method of the
Berthelot reaction with Urea Nitrogen Colorimetric Reagent (Teco
Diagnositcs, Anaheim, CA, USA) and HPLC method50 respectively.
Serum potassium, aspartate aminotransferase, and alanine amino-
transferase were measured using an autoanalyzer (Hitachi 917,
Boehringer Mannheim, Indianapolis, IN, USA). Plasma VEGF and
IL-10 were measured by enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN, USA).
Vascular permeability assay with Evans blue dye
Mice were injected intravenously with 20 mg/kg Evans blue dye
(Sigma-Aldrich). Thirty minutes after injection, peritoneal fluid was
collected with 1.5 ml NS lavage. Mice were perfused with phosphate-
buffered saline through the right ventricle until blood was visibly
eliminated. The kidneys and lungs were weighed, snap frozen in
liquid nitrogen, and stored at 80 1C. Peritoneal fluid was
centrifuged for 10 min at 3000 g. The kidneys and lungs were
homogenized in 1 ml formamide and incubated 55 1C for 18 h and
centrifuged at 10,000 g for 30 min. The amount of Evans blue dye in
the supernatants was analyzed by measuring absorbance at 620 and
740 nm as described previously.51 Results were expressed as
concentration of Evans blue dye in peritoneal fluid lavage and
micrograms of Evans blue dye per gm of kidney or lung (wet
weight).
Bacterial count in blood and peritoneal cavity
The peritoneal cavity was lavaged with 1.5 ml sterile saline, and
blood was collected by cardiac puncture 18 h after CLP surgery.
Serial dilutions of blood or peritoneal fluid were plated onto tryptic
soy agar (Remel, Lenexa, KS, USA) and colony counting after 24 h
incubation at 37 1C. Bacterial counts were log normalized; samples
that did not have detectable bacteria were assigned a value of 0.5
colony forming unit.
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Morphologic evaluation of kidney and lung
Kidney and lung specimens (4mm), fixed in 10% formalin and
embedded in paraffin, were stained with Masson’s trichrome and
hematoxylin and eosin staining, respectively. Renal tubular damage
caused by CLP-induced sepsis was assessed by counting vacuolized
tubules at  400 magnification using 4100 randomly selected
tubules from each animal.10,11
Immunohistochemical analysis of activated caspase-3 in
spleen
Immunohistochemical staining of 4 mm paraffin sections was
performed with anti-activated caspase-3 antibody (Cell Signaling
Technology, Beverly, MA, USA) as described previously.52 The
number of positive stained cells was determined from the mean of
five randomly selected nonoverlapping 200 fields in each section.
Statistical analysis
Results are expressed as mean±s.e.m. Differences among groups
were analyzed by Student’s t-test or Mann–Whitney rank sum test.
Differences among groups in the combination treatment experi-
ments were confirmed by one-way ANOVA followed by Dunnett’s
test for individual comparison. Survival analyses were compared by
a log-rank test with a multiple comparison correction. These
calculations were done using SigmaStat version 3.10 (Systat Software
Inc., Richmond, CA, USA). The null hypothesis was rejected when
Po0.05.
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